

**Serum Concentrations of Polybrominated Diphenyl Ethers  
(PBDEs) and Polybrominated Biphenyl (PBB) in the United  
States Population: 2003-2004**

Andreas Sjödin\*, Lee-Yang Wong, Richard S. Jones, Annie Park, Yalin Zhang, Carolyn Hodge, Emily DiPietro, Cheryl McClure, Wayman Turner, Larry L. Needham and Donald G. Patterson, Jr.

Centers for Disease Control and Prevention; National Center for Environmental Health;  
4770 Buford Hwy NE, Atlanta, GA, 30341, USA.

\* - Corresponding author

Contact information for corresponding author:

Phone: +1-770-488-4711

Fax: +1-770-488-0142

Email: [asjodin@cdc.gov](mailto:asjodin@cdc.gov)

**Brief Study Description:** Assessment of the exposure status of the U.S. population to PBDEs and BB-153 and associations with demographic information, including participants' age, sex and race/ethnicity.

**Key words:** Polybrominated Diphenyl Ethers (PBDEs)

Polybrominated Biphenyl (PBB)

NHANES

Biomonitoring

Reference Values

## Abstract

Polybrominated diphenyl ethers (PBDEs) and 2,2',4,4',5,5'-hexabromobiphenyl (BB-153) are chemicals known as brominated flame retardants. We have assessed the exposure status of the U.S. population to PBDEs and BB-153 and explored associations with demographic information, including participants' age, sex and race/ethnicity. 2,062 serum samples, from participants in the National Health and Nutrition Examination Survey (NHANES) 2003-2004 aged 12 years and older, were analyzed for PBDEs and BB-153; stratified and regression analyses were used to examine levels among demographic groups.

The congener with the highest serum concentration was 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) [geometric mean 20.5 ng/g lipid]; followed by 2,2',4,4',5,5'-hexaBDE (BDE-153) [5.7 ng/g lipid]; 2,2',4,4',5-pentaBDE (BDE-99) [5.0 ng/g lipid; a value equal to the highest limit of detection for an individual sample]; 2,2',4,4',6-pentaBDE (BDE-100) [3.9 ng/g lipid]; BB-153 [2.3 ng/g lipid]; and 2,4,4'-triBDE (BDE-28) [1.2 ng/g lipid]. For BDE-47, we observed no significant difference in the least square geometric mean (LSGM) by sex, but with age we found both a linear decrease ( $p=0.01$ ) and a positive quadratic trend ( $p=0.01$ ). Its LSGM, 27.9 ng/lipid, in the 12-19 year olds decreased to 17.2 ng/g lipid in the 40-49 year group, and then curved upwards to 20.4 ng/g lipid in the  $\geq 60$  years olds. Mexican Americans had the highest LSGM of BDE-47 (24.5 ng/g lipid), which was significantly higher than that of Non-Hispanic whites (19.7 ng/g lipid,  $p=0.01$ ). Adults 60 years and older were twice as likely as adults 20-59 years old to have a serum BDE-47 concentration above the 95<sup>th</sup> percentile ( $p=0.02$ ). These data provide needed exposure assessment data for public health decisions.

## Introduction

The National Health and Nutrition Examination Survey (NHANES) provides an ongoing exposure assessment of the civilian, non-institutionalized U.S. population to a wide range of chemicals through biomonitoring. The survey results are reported in CDC's *National Report on Human Exposure to Environmental Chemicals (1)*. We report here individual serum concentrations of polybrominated diphenyl ethers (PBDEs) and 2,2',4,4',5,5'-hexabromobiphenyl (BB-153), based on NHANES sampling conducted during the years 2003 and 2004.

PBDEs and BB-153 are chemicals commonly known as brominated flame retardants (BFRs), of which PBDEs are the most well known class (2). BB-153, on the other hand, is an older use BFR; its production was discontinued in the mid-1970s in the U.S. after its accidental contamination into dairy feed (3) in the State of Michigan. This incident led to wide spread exposure to cattle and poultry; to humans who consumed these food items; and to breast feeding infants of exposed mothers (3).

PBDEs are produced in three different technical preparations, commonly named according to their average bromine content; i.e., PentaBDE, OctaBDE, and DecaBDE (4). Technical PentaBDE is a mixture of congeners containing approximately 37% by weight tetraBDEs, 43% pentaBDEs and 6.8% hexaBDEs and trace levels of triBDEs and heptaBDE (5). Technical OctaBDE is a mixture of congeners with six to eight bromine atoms on the diphenyl ether backbone while the DecaBDE mixture almost exclusively contains BDE-209 (6). PBDE congeners containing seven to ten bromine atoms have

relatively short biological half-lives in humans; e.g., 2,2',3,4,4',5',6-heptabromophenyl ether (BDE-183) has a half-life of 94 days (95% CI 68-120 days) (7). These highly brominated congeners are not likely to biomagnify through the food chain, and thus direct exposures in the indoor environment and occupational exposures are most likely the dominant pathways of human exposure. The half-lives of PBDE congeners with fewer than seven bromine substituents have not been determined in humans, although, the 2,2',4,4',5,5'-hexabromodiphenyl ether (BDE-153) half-life has been estimated to be in the range of 2 years (8).

The PentaBDE formulation has been used primarily in the U.S. Of the 7,500 metric tonnes of technical PentaBDE produced in 2001, ~95% were consumed in North America (9). The PentaBDE product is used in most modern homes in the U.S. as a flame retardant in polyurethane, which is used in furniture applications and in the foam padding under wall-to-wall carpets (4,10). The PBDEs originating from the PentaBDE mixture have been reported at much higher concentrations in residential dust from the U.S. than from Germany, England, and Australia (11) and in serum samples worldwide (12-17). Technical PentaBDE and OctaBDE were voluntarily phased out in the United States beginning at the end of 2004. However, because of the wide spread distribution in U.S. homes, as measured in the indoor environment (11,18-20), and high environmental levels, as measured and documented in, for example, herring gull eggs from the Great Lakes (21), it is likely that human body burdens in the United States will remain higher than European levels in the near future.

The OctaBDE and DecaBDE preparations are used in hard plastics, such as those found in the casings of electronic equipment. The 2001 industrial consumptions of OctaBDE and DecaBDE in the United States were estimated to be 1,500 and 24,500 metric tones per year (9), respectively, which represent 40% and 44% of the total world market, respectively.

From a toxicological standpoint, PBDEs have been shown to cause neurodevelopmental effects, as measured by altered habituation patterns in pups born from mice dosed during a critical window of the developing mice fetus (22). These experiments also indicated that 2,2',4,4',5-pentabromodiphenyl ether (BDE-99) is more potent than 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) (22). Potential toxicological endpoints of concern for PBDEs also include thyroid hormone disruption and cancer (23).

We report here serum concentrations of ten PBDE congeners (tri- to heptaBDEs) and BB-153 (Table 1) in a representative sampling of U.S. residents in 2003 and 2004; we assess the variation of concentrations by age, sex, and race/ethnicity. Further, the influences of life style factors, such as the age of the primary residence and country of origin have been investigated. DecaBDE was not included in this survey due to difficulties with analytical measurement.

## **Experimental Section**

*Survey overview and sampling:* The National Center for Health Statistics (NCHS) and the National Center for Environmental Health (NCEH), both of the Centers for

Disease Control and Prevention (CDC), administered NHANES and performed the analytical analyses, respectively. The goal of the NHANES is to obtain a representative sample of the non-institutionalized population residing in the United States and thus by assessing the health and nutrition status of this sub-sample of the population, estimate the status of the population as a whole. A statistically representative sample of the population is collected by dividing the country into geographic areas known as primary sampling units (PSUs). The PSUs are then combined to form strata, each strata is then divided into a series of neighborhoods. Households are thereafter chosen at random from these neighborhoods, and residents are interviewed to determine eligibility for participation in the survey. Over sampling of demographic groups, such as Mexican Americans and the socioeconomic underserved, ensures reliable sample size for these demographic groups. This over sampling is adjusted during data analyses by sampling weights. Each year approximately 5,000 subjects are recruited from 15 locations across the United States. Although, the NHANES is not designed to assess geographical differences. A random one-third subset of eligible participants (N=2,305) age 12 years and above of the NHANES 2003/04 survey was chosen for measurement of BFRs. Of these, 2,062 serum samples were available for analysis. The population consisted of 48.4% male subjects. The race/ethnicity distribution of the sample was 71.5% non-Hispanic white (NHW), 12.0% non-Hispanic black (NHB) and 8.2% Mexican Americans (MA); other race/ethnicity groups corresponded to 8.3%. The percentages of participants below the age of 20 years and above the age of 60 years were 12.2 and 17.0%, respectively.

**Analytical Methods:** All sample preparation work was performed in a clean room; its supply air is passed through UPLA (Ultra-Low Penetration Air) filters, which have a 99.999% efficiency for removal of particles of 0.12 $\mu$ m diameter or larger. Inside the clean room, biological safety cabinets are used as a second barrier against particle contamination during all phases of sample handling. The analytical methodology employed for the measurement of BFRs in serum has been reported (24); detailed information on the determination of the limit of detection (LOD) is given in Supplemental Information 1.

**Statistical Methods:** SAS software (version 9.1.3, SAS Institute, Cary, NC) and SUDAAN software (version 9.0.1, Research Triangle Institute, Research Triangle Park, N.C) were used to produce estimates, regression coefficients, and related standard errors. We used sample weights to account for the unequal probability of selection and log transformed data to compute all the estimates. Geometric means are calculated for analytes detected in  $\geq 60\%$  of the samples. For a concentration below the maximum LOD, a value equal to the LOD divided by the square root of 2 was used. Weighted Pearson correlation coefficients were calculated in SAS.

For race/ethnicity group, we included everyone in the calculation for total estimates, but we only used MA, NHB and NHW for other descriptive analyses and for regression analyses. We stratified age by 12-19, 20-39, 40-59 years old and 60 years and older for the geometric mean and the various percentiles.



We compared the brominated chemical concentrations by the participants' country of birth (inside or outside of US; variable DMDBORN) and by the construction year of the residents' housing (before 1959, 1960 – 1977, and 1978 and later). Because only 74.5% of the participants responded to construction year of the residents question and because the number of the foreign born was very small in the NHW (n=50) and the NHB (n=52), we did not include these two variables in the multiple regression.

We used analysis of covariance to examine the influence of demographic variation of the log-transformed serum concentrations for the analytes with  $\geq 60\%$  detection frequency; i.e., BB-153, BDE-28, BDE-47, BDE-99, BDE-100, and BDE-153. The least square geometric mean (LSGM) was calculated from the regression model. For multiple regression analyses, the variables included in the initial model are age (continuous), sex (Male or Female), and race (MA, NHB, and NHW). We also included an age-squared term in the model for BB-153, BDE-28, BDE-47, BDE-99, BDE-100, and BDE-153 because the unadjusted geometric mean by age groups indicated a curvilinear relationship between age and the PBDE lipid-adjusted serum concentration. When both age and age-squared were included in the model, we found that age and age-squared terms had the least correlation at age 46 year old, so to avoid multi-collinearity, we subtracted 46 from each participant's age (25). We assessed all possible two-way interaction terms in the model. To evaluate the relation between the log-transformed concentration of all analytes and age, we changed the continuous age to be a categorical age-decades variable in the model in order to generate a bar chart of LSGM concentrations by age decades.

To reach the final model, we used backward elimination with a threshold of  $p < 0.05$  for retaining the variable in the model, using Satterwaite-adjusted F statistics. We evaluated for potential confounding by adding each of the excluded variables back into the final model one by one and examining changes in the  $\beta$  coefficients of the statistically significant main effects. If addition of one of these excluded variables caused a change in a  $\beta$  coefficient by  $\geq 10\%$ , the variable was added back into the model.

We conducted weighted univariate and multiple logistic regression to examine the association of BDE-47 or BDE-153 concentrations above the 95<sup>th</sup> percentile with sex (Male, Female), age (12-19, 20-59, and 60 year and older), and race/ethnicity. These congeners were selected since they are the in concentration dominating congeners.

## **Results**

The serum concentrations of ten PBDE congeners with three to seven bromine substituents and BB-153 were measured in 2,062 serum samples from the NHANES 2003/04; 99% were analyzed successfully giving a total of 2,040 samples with data available for statistical analysis. BDE-47 was measured above its LOD in 2016 samples and also the concentration of this congener was the highest in all stratifications of the population and the entire population. Its geometric mean concentration in all participants was 20.5 ng/g lipid; followed by BDE-153 (5.7 ng/g lipid), BDE-99 (5.0 ng/g lipid; a value equal to the highest limit of detection for an individual sample), BDE-100 (3.9 ng/g lipid), BB-153 (2.3 ng/g lipid) and BDE-28 (1.2 ng/g lipid) (Tables 2-3). Geometric means could not be calculated for BDE-17, BDE-66, BDE-85, BDE-154 and BDE-183

because these congeners had a detection frequency of less than 60% (Table 1). The geometric mean concentration and various percentiles stratified by age groups (age 12-19; 20-39; 40-59 and  $\geq 60$  years), race/ethnicity (MA, NHB, NHW) and sex are given in Tables 2-3 and Figure 1 for congeners with a detection frequency above 60%, while congeners with a lower detection frequency are given in Table S1.

When examining these data by multiple regression, the final model for BB-153 included sex, age, age-square ( $p < 0.01$ ), race ( $p < 0.01$ ) and an interaction term between age and sex ( $p = 0.02$ ); for BDE-28, age ( $p = 0.18$ ) and age-squared ( $p = 0.04$ ); for BDE-47, race ( $p = 0.06$ ), age ( $p = 0.01$ ), and age-squared ( $p = 0.01$ ); for BDE-99, race ( $p = 0.02$ ), age ( $p = 0.01$ ), and age-squared ( $p < 0.01$ ); for BDE-100, age ( $p < 0.01$ ), and age-squared ( $p = 0.045$ ); and for BDE-153, sex ( $p < 0.01$ ), age ( $p < 0.01$ ), and age-squared ( $p = 0.02$ ).

We observed a curvilinear relationship between the log-transformed lipid-adjusted BDE-47 concentration and age (Tables S2-S3, Figure S1). We found both a linear decrease and positive quadratic trend with age (linear  $p = 0.01$ , quadratic  $p = 0.01$ ), cf. Table S3. The LSGM of BDE-47 had the highest level (27.9 ng/g lipid) in the 12-19 years old and decreased through the 40-49 years age group (17.2 ng/g lipid) and then curved upwards to reach 20.4 ng/g lipid in the  $\geq 60$  year olds. MA participants had the highest LSGM of BDE-47 (24.5 ng/g lipid), which was significantly higher than for NHW (19.7 ng/g lipid,  $p = 0.01$ ). MA and NHB had similar LSGMs for BDE-47 concentrations. Similarly, no significant difference of LSGMs for BDE-47 concentrations was observed between males and females.

For log-transformed lipid adjusted BDE-153, we also observed a similar curvilinear trend with age—both a linear decrease ( $p < 0.01$ ) and a positive quadratic ( $p = 0.02$ ) trend (Tables S2-S3). The LSGM of BDE-153 had the highest level in the 12-19 years old (8.0 ng/g lipid). Female participants had significantly lower BDE-153 lipid adjusted concentrations than males ( $p < 0.01$ ). No significant difference of the LSGMs for BDE-153 concentrations was observed between race/ethnicity groups.

For BDE-99, we also observed a curvilinear relationship with age (Tables S2-S3). The LSGM of lipid-adjusted BDE-99 concentrations was the highest in the 12-19 years old (6.8 ng/g lipid). We observed a linear decreasing trend ( $p < 0.01$ ) as well as a positive quadratic trend with age ( $p = 0.01$ ). For BDE-99: NHB participants had the highest LSGM (6.1 ng/g lipid), which was significantly higher than the LSGM for NHW (4.8 ng/g lipid,  $p = 0.02$ ). The LSGM of NHW was significantly lower than the LSGM for MA (5.7 ng/g lipid,  $p = 0.046$ ). There was no significant difference in the LSGMs for BDE-99 between NHB and MA, nor between males and females.

Similarly, we observed the curvilinear relationship between age and the log-transformed lipid adjusted BDE-100 concentration. The highest LSGM of BDE-100 was in the 12-19 years old with both a linear decreasing trend ( $p < 0.01$ ) and a quadratic trend ( $p = 0.045$ ). There was no significant difference in the LSGMs of BDE-100 among race/ethnicity groups or between the sexes.

Although there was a curvilinear relationship between age and the log-transformed lipid adjusted BDE-28 concentration, only the positive quadratic curve was significant ( $p=0.04$ ). No significant difference for LSGM of BDE-28 was observed between race/ethnicity groups or between sexes.

For the log-transformed concentration of BB-153, there was a relationship with age (Tables S2-S3 and Figure S1) characterized by a positive linear trend ( $p<0.01$ ) and a small negative quadratic trend ( $p<0.01$ ). We also observed that both males and females had an increasing LSGM with age ( $p<0.01$  for both male and female); however, concentrations in males increased more sharply with age than in females ( $\beta=0.002$ ,  $p=0.02$ ). The LSGM of BB-153 in males is significantly higher than in female regardless of age ( $p<0.001$ ). The LSGM of both NHB and NHW were higher than that of MA ( $p=0.001$  and  $p<0.001$  for NHB and NHW, respectively). NHB and NHW had similar LSGM concentrations of BB-153.

Relating to potential pathways of exposure, we note that all PBDE congeners with a detection frequency over 60% were significantly correlated with each other (Table S4). BB-153 was significantly correlated ( $p=0.04$ ) only with BDE-47 (Table S4). BDE-153 was found at a higher concentration than BDE-47 in 10.5% of the participants. The median ratio of BDE-153 to BDE-47 was 0.54 (quartile range 0.38-0.75).

BB-153 was found at 18% higher geometric mean concentration in participants living in housing constructed between 1960-77 as compared to participants living in housing

constructed after 1978 ( $p=0.03$ ), cf. Table 4. The geometric means of BDE-47 and BDE-153 did not vary significantly with the age of the participant's primary residence (Table 4). The geometric mean of BDE-153 was found to be 31% lower ( $p<0.01$ ) in foreign born subjects than in participants born in the United States, while for BDE-47 no significant difference was observed between these groups (Table 4). The geometric mean for BB-153 was 62% lower in foreign born participants as compared to participants born in the U.S. ( $p<0.01$ ).

In examining those with the highest serum concentrations (above the 95<sup>th</sup> percentile) of BDE 47, age, but not sex and race/ethnicity, was significantly associated. Senior adults (60 years and older) were two times more likely to be above the 95<sup>th</sup> percentile than adults 20-59 years old ( $p=0.02$ ) (odds ratio (OR) (95% CI): 2.0 (1.1, 3.6)); and 54% more likely than adolescents to be above the 95<sup>th</sup> percentile ( $p=0.067$ ) (OR (95%CI): 1.5 (1.0, 2.5). There was no difference in the likelihood of being above the 95<sup>th</sup> percentile between the 12-19 and 20-59 year old age groups.

For BDE-153, sex and race, but not age, were significantly associated with being above the 95<sup>th</sup> percentile univariately ( $p=0.018$ , 0.03 for sex and race, respectively). In the final multiple logistics regression, sex ( $p=0.04$ ) and race ( $p=0.03$ ) were significant. We found that males were 2.1 times more likely than females to be above the 95<sup>th</sup> percentile (adjusted OR (95%CI): 2.1 (1.0, 4.3)). MA were 62% less likely than NHW to be above the 95<sup>th</sup> percentile ( $p=0.03$ ) (adjusted OR (95%CI): 0.38 (0.15, 0.91). There was no significant difference between NHB and MA.

## Discussion

These NHANES data from a representative civilian, non-institutionalized US population assess the internal dose concentrations of PBDE congeners and of BB-153, the congener of highest concentration in commercial PBBs. Among the PBDE congeners, BDE-47 was detected in serum from almost all of the participants and at the highest concentrations. Compared to median data from smaller non-representative European studies, the median NHANES BDE-47 serum concentration of 19.2 ng/g lipids is 7.1-35 times higher (13-15). Among the PBDE congeners, in general BDE-47 serum concentrations were the highest, but 10.5% of persons had higher BDE-153 concentrations, which is present in both the PentaBDE and OctaBDE formulations (6); these formulations have different commercial applications. Because of the short serum half life of BDE-183, which is found only in the OctaBDE formulation, BDE-153 concentrations or the ratio of concentrations of BDE-153/BDE-47 could potentially reflect exposure to the OctaBDE formulation, although, the variance in this ratio could potentially also be explained by differences in pharmacokinetics. The presence of BDE-153 in the two formulations is also indicated by the lower correlation coefficients between its concentrations and those of the other prevalent PBDE congeners, which are found only in the PentaBDE formulation (Table S4).

In multiple regression models, we observed both a significant linear decrease and a positive quadratic trend with age for PBDE congeners detectable in more than 60% of the participants (Tables S2-S3), in contrast to the traditional chlorinated persistent organic

pollutants which tend to increase as age increases (26). The higher concentrations in the youngest age groups examined (Tables S2-S3) are probably due to their lifestyle and activity differences, which lead to higher exposures, although potential differences in the pharmacokinetics of these chemicals in their bodies must be considered. The slight increase in the oldest participants could potentially be explained by bioaccumulation and/or by a slower metabolism and elimination of PBDEs at an older age.

For public health decisions, scientists are especially interested in persons with concentrations above the 95<sup>th</sup> percentile. For BDE-47 concentrations, participants aged 60 years and older were twice as likely to be above the 95<sup>th</sup> percentile as those aged 20-59 years. With regards to race/ethnicity, the BDE-47 LSGM of MA was significantly higher than for NHW; however, although this was not statistically significant, the likelihood for being above the 95<sup>th</sup> percentile was greater for NHW than for MA. For BDE-153, we did see differences with sex and race/ethnicity as males were twice as likely as females to have a concentration greater than the 95<sup>th</sup> percentile. This difference in concentrations between the sexes is consistent with the LSGM data for BDE-153. Also, NHW were more likely than MA to have a BDE-153 concentration above the 95<sup>th</sup> percentile, which was not indicated with the LSGM data from multiple regression analyses. The finding that MA participants are less likely to have the higher serum concentrations of BDE-153 as well as BB-153 is consistent with a higher proportion of immigrants who likely experienced a lower level of exposure in their country of origin, cf. Table 4.



In multiple regression models, the LSGMs of BB-153 increased linearly with age with a relatively small significantly negative quadratic term and a sex interaction term. An increasing concentration of BB-153 with age (Tables S2-S3) is consistent with other traditional chlorinated persistent organic pollutants (POPs) (26) that were phased out in the 1970s. This increasing trend is because older participants have been exposed to BB-153 for a longer period of time than younger participants and that the older participants also were exposed to these chemicals when the environmental levels were higher than today. For BB-153, higher LSGM concentrations were found in males in all age and race/ethnicity groups (Figure S1 and Tables S2-S3); this differs somewhat from data for traditional POPs which were found in higher concentrations in older females compared to older males (26). The observed sex difference may potentially be explained by depuration during nursing.

In addition to lower BB-153 concentrations being found in MA, the geometric mean for BB-153 was 62% lower in foreign born participants compared to participants born in the United States ( $p < 0.001$ ), cf. Table 4. We also found a significantly higher geometric mean BB-153 concentration in participants living in housing constructed between 1960 and 1977 (2.6 ng/g lipid; 95% CI 2.0-3.4) compared to participants living in housing constructed after 1978 (2.2 ng/g lipid; 95% CI 1.8-2.7,  $p = 0.03$ ). This observed difference in geometric mean concentration by the construction year of primary residence could be explained by the fact that BB-153 was phased out in the U.S. in the mid-1970s and hence would be less likely to be found in homes constructed after 1978. Also, BDE-153 was found at a lower geometric mean concentration in foreign born participants (4.1 ng/g

lipid; 95% CI 3.3-5.0) than in participants born in the United States (6.0 ng/g lipid; 95% CI 5.4-6.7,  $p=0.01$ ). This difference is most likely explained by a higher exposure level to BDE-153 in the United States than abroad.

The 95th percentile for the sum of PBDEs was 291 ng/g lipid (95% CI, 224-540). The highest sum of PBDE levels observed in the NHANES 2003-2004 participants was 3,680 ng/g lipid, which included BDE-47 at 2,350 ng/g lipid and concentrations of BDE-99, BDE-100 and BDE-153 at 692, 339 and 152 ng/g lipid, respectively. In this individual, the level of 2,2',4,4',5,5'-hexachlorobiphenyl (CB-153) was only 13 ng/g lipid, indicating low exposure to PCBs (*1*). The concentration of BDE-47 was 180 times higher than that of CB-153. Children less than 12 years of age and some PBDE congeners, such as BDE-209, were not included in NHANES 2003-04. Based on a NHANES 2001-2002 serum pool study the mean concentration of BDE-209 is about 2 ng/g lipids in those 12 years of age and older (unpublished data); therefore, BDE-209 is unlikely to contribute significantly to the total PBDE concentration. We are currently analyzing similar serum pools in children aged 3- 11 years.

Although there have been no human health effects directly attributed to exposure to PBDEs and animal data are limited, public health concern has been expressed regarding the potential exposure to these persistent environmental chemicals (*9*). A recent time trend study of U.S. residents, although non-representative, showed increasing serum PBDE concentrations from the mid-1980s to 2002 (*27*). In future studies, it will be of interest to compare changes in concentrations over time, particularly in light of the

discontinuation of the PentaBDE and OctaBDE production in the U.S. It is also important to conduct studies that will target children and workers in certain occupational settings and to focus on life style factors that result in exposures that produce the higher serum concentrations of PBDEs.

### **Acknowledgement**

The authors would like to acknowledge the hard work of those who contributed to this work but are not listed as coauthors: Jeff Vancura for his expertise in high resolution mass spectrometry, Cheryl McClure for database handling, Troy Cash for logistical support, and Sarah Niehüser for proof reading this manuscript.

### **Supporting Information Available**

Additional information are given in Tables S1-S4 and Figure S1 and supporting information (SI-1). This material is available free of charge via the Internet at <http://pubs.acs.org>.

**Table 1.** Polybrominated diphenyl ethers and brominated biphenyl measured and their abbreviations. Total number of valid measurements and percentage of measurements above the limit of detection (LOD) and the maximum LOD applied.

Analyte	Abbreviation	# measured	% >LOD	Maximum LOD
<b><i>Polybrominated Diphenyl Ethers (PBDEs)</i></b>				
2,2',4-tribromodiphenyl ether	BDE-17	1992	5	1.0
2,4,4'-tribromodiphenyl ether	BDE-28	1987	79	0.8
2,2',4,4'-hexabromodiphenyl ether	BDE-47	2016	97	4.2
2,3',4,4'-tetrabromodiphenyl ether	BDE-66	1999	21	1.0
2,2',3,4,4'-pentabromodiphenyl ether	BDE-85	2000	23	2.4
2,2',4,4',5-pentabromodiphenyl ether	BDE-99	1985	65	5.0
2,2',4,4',6-pentabromodiphenyl ether	BDE-100	2040	93	1.4
2,2',4,4',5,5'-hexabromodiphenyl ether	BDE-153	2039	93	2.2
2,2',4,4',5,6'-hexabromodiphenyl ether	BDE-154	2014	51	0.8
2,2',3,4,4',5',6-heptabromodiphenyl ether	BDE-183	1993	15	1.7
<b><i>Polybrominated Biphenyl (PBB)</i></b>				
2,2',4,4',5,5'-hexabromobiphenyl	BB-153	2032	83	0.8

**Table 2.** Geometric mean (GM) concentrations (ng/g lipid), selected percentiles, and their 95% confidence intervals (95% CI) for 2,4,4'-tribromodiphenyl ether (BDE-28), 2,2',4,4'-hexabromodiphenyl ether (BDE-47) and 2,2',4,4',5-pentabromodiphenyl ether (BDE-99) for all participants in the NHANES 2003/04 stratified by age, race/ethnicity and sex . The limits of detection are given in Table 1. All data adjusted for design sampling weights.

Demographic Group	Geomean		Percentiles				
	GM (95% CI)	P10 (95% CI)	P25 (95% CI)	P50 (95% CI)	P75 (95% CI)	P90 (95% CI)	P95 (95% CI)
<b>2,4,4'-tribromodiphenyl ether (BDE-28)</b>							
All Participants	1.2(1.0-1.4)	<LOD	<LOD	1.1(0.9-1.2)	2.1(1.9-2.5)	4.8(3.3-6.7)	7.9(5.3-10.9)
<b>Age Groups</b>							
12-19 Years	1.3(1.2-1.5)	<LOD	<LOD(<LOD-0.8)	1.2(1.0-1.3)	2.3(2.0-2.6)	3.9(2.8-4.9)	6.0(4.0-9.4)
20-39 Years	1.1(1.0-1.3)	<LOD	<LOD	1.1(0.8-1.3)	1.9(1.5-2.3)	3.4(2.4-5.1)	6.1(3.7-9.3)
40-59 Years	1.1(0.9-1.3)	<LOD	<LOD	1.0(0.8-1.3)	2.1(1.7-2.7)	4.7(2.8-8.3)	8.2(4.6-11.8)
> 60 Years	1.4(1.1-1.7)	<LOD	<LOD	1.1(0.9-1.4)	3.2(2.1-4.8)	6.6(5.6-7.7)	9.6(7.2-18.1)
<b>Race/Ethnicity</b>							
MA	1.4(1.3-1.6)	<LOD	<LOD(<LOD-0.8)	1.4(1.2-1.5)	2.3(1.9-2.8)	4.7(3.7-5.5)	7.3(5.6-8.3)
NHB	1.2(1.0-1.4)	<LOD	<LOD	1.0(0.8-1.2)	2.1(1.8-2.4)	5.2(3.5-6.7)	8.4(5.4-12.3)
NHW	1.2(1.0-1.4)	<LOD	<LOD	1.1(0.8-1.3)	2.2(1.8-2.7)	4.8(3.0-8.0)	8.0(4.5-13.6)
<b>Sex</b>							
Females	1.2(1.0-1.4)	<LOD	<LOD	1.0(0.8-1.3)	2.1(1.7-2.5)	4.6(3.0-6.7)	7.7(4.7-11.8)
Males	1.2(1.1-1.4)	<LOD	<LOD	1.0(0.9-1.2)	2.2(2.0-2.7)	5.1(3.5-7.3)	8.0(5.7-11.3)
<b>2,2',4,4'-hexabromodiphenyl ether (BDE-47)</b>							
All Participants	20.5(17.6-23.9)	5.0(4.3-6.1)	9.3(8.2-10.9)	19.2(15.7-22.3)	40.9(35.6-49.2)	84.9(66.8-127.0)	157.0(108.0-240.0)
<b>Age Groups</b>							
12-19 Years	28.2(24.6-32.3)	7.8(5.2-10.6)	14.1(12.0-16.6)	27.2(22.1-33.6)	53.6(44.9-63.6)	104.0(82.4-145.0)	174.0(115.0-211.0)
20-39 Years	21.5(18.3-25.4)	6.5(4.8-7.5)	10.3(9.2-12.0)	21.6(17.0-25.1)	38.3(34.8-44.2)	72.0(53.0-102.0)	114.0(73.9-216.0)
40-59 Years	17.7(14.4-21.7)	4.6(<LOD-5.5)	7.7(6.3-10.0)	14.7(12.3-19.2)	35.8(27.1-50.8)	84.9(54.9-142.0)	142.0(94.3-240.0)
> 60 Years	19.7(15.8-24.5)	<LOD (<LOD-5.0)	7.7(6.1-9.1)	16.9(13.2-21.7)	48.9(31.2-70.7)	108.0(81.4-173.0)	235.0(171.0-283.0)
<b>Race/Ethnicity</b>							
MA	25.5(23.0-28.1)	8.0(7.2-9.1)	12.0(10.9-14.4)	23.4(21.2-25.5)	47.1(38.2-56.5)	85.8(72.0-105.0)	151.0(104.0-188.0)
NHB	24.3(20.9-28.2)	6.0(4.8-7.4)	10.3(9.3-11.2)	21.3(18.2-25.4)	47.5(40.7-53.2)	116.0(81.8-149.0)	242.0(136.0-481.0)
NHW	19.5(16.1-23.7)	4.7(<LOD-5.6)	8.6(7.5-10.1)	17.3(14.4-22.2)	40.2(33.1-51.9)	85.1(60.3-142.0)	157.0(90.2-283.0)
<b>Sex</b>							
Females	19.6(16.4-23.5)	4.8(<LOD-6.1)	9.2(8.0-10.7)	19.1(13.9-23.0)	38.3(31.5-44.7)	79.2(60.7-121.0)	155.0(102.0-235.0)
Males	21.4(18.1-25.3)	5.1(<LOD-6.6)	9.5(7.8-11.3)	19.2(15.7-24.0)	45.2(37.3-54.9)	94.3(66.8-148.0)	168.0(112.0-382.0)
<b>2,2',4,4',5-pentabromodiphenyl ether (BDE-99)</b>							
All Participants	5.0(4.4-5.6)	<LOD	<LOD	<LOD	9.2(7.5-10.9)	21.7(17.0-29.1)	42.2(33.3-54.8)
<b>Age Groups</b>							
12-19 Years	6.9(6.1-7.7)	<LOD	<LOD	5.6(<LOD-7.6)	12.8(11.4-15.7)	27.9(19.6-37.9)	45.2(35.9-56.8)
20-39 Years	5.2(4.4-6.1)	<LOD	<LOD	<LOD(<LOD-5.6)	8.3(7.1-10.6)	18.0(13.2-22.6)	28.8(20.4-52.7)
40-59 Years	*	<LOD	<LOD	<LOD	8.7(5.5-10.9)	19.7(14.4-31.9)	41.2(25.1-80.7)
> 60 Years	*	<LOD	<LOD	<LOD	9.4(6.5-12.8)	29.3(15.3-47.9)	52.3(33.5-74.0)
<b>Race/Ethnicity</b>							
MA	5.9(5.5-6.4)	<LOD	<LOD	5.4(<LOD-5.7)	10.6(9.3-12.6)	20.0(17.0-23.5)	30.8(24.5-41.7)
NHB	6.2(5.4-7.1)	<LOD	<LOD	5.0(<LOD-5.7)	11.3(9.5-12.8)	30.2(21.5-42.2)	74.7(30.2-155.0)
NHW	*	<LOD	<LOD	<LOD	8.8(6.8-11.3)	21.5(15.3-34.0)	43.6(30.7-71.4)
<b>Sex</b>							
Females	*	<LOD	<LOD	<LOD	8.6(6.6-10.6)	18.3(14.7-28.8)	41.2(22.9-60.3)
Males	5.3(4.5-6.1)	<LOD	<LOD	<LOD(<LOD-5.1)	10.0(8.4-11.5)	23.8(18.0-37.3)	44.0(33.8-57.3)

Abbreviations: MA, Mexican Americans; NHB, Non-Hispanic Black; NHW, Non-Hispanic White. \* Estimate is below the highest limit of detection for individual samples.

**Table 3.** Geometric mean (GM) concentrations (ng/g lipid), selected percentiles, and their 95% confidence intervals (95% CI) for 2,2',4,4',6-pentabromodiphenyl ether (BDE-100), 2,2',4,4',5,5'-hexabromodiphenyl ether (BDE-153) and 2,2',4,4',5,5'-hexabromobiphenyl (BB-153) for all participants in the NHANES 2003/04 stratified by age, race/ethnicity and sex . The limits of detection are given in Table 1. All data adjusted for design sampling weights.


Demographic Group	Geomean	Percentiles					
	GM (95% CI)	P10 (95% CI)	P25 (95% CI)	P50 (95% CI)	P75 (95% CI)	P90 (95% CI)	P95 (95% CI)
<b>2,2',4,4',6-pentabromodiphenyl ether (BDE-100)</b>							
All Participants	3.9(3.4-4.5)	<LOD	1.6(1.5-2.0)	3.6(3.1-4.1)	7.8(6.8-9.0)	18.3(15.4-22.0)	36.5(24.6-54.0)
<b>Age Groups</b>							
12-19 Years	5.2(4.5-6.0)	<LOD (<LOD-1.8)	2.6(2.2-3.1)	4.8(3.8-6.1)	9.4(7.9-12.8)	19.3(14.4-26.2)	34.3(25.0-45.0)
20-39 Years	4.4(3.7-5.2)	<LOD	2.1(1.7-2.6)	4.1(3.3-5.0)	8.0(6.6-10.0)	17.1(13.2-21.1)	23.6(19.7-47.1)
40-59 Years	3.3(2.8-4.1)	<LOD	<LOD (<LOD-1.6)	2.8(2.1-3.4)	6.2(5.3-7.5)	16.3(10.5-29.2)	40.5(19.5-91.6)
> 60 Years	3.6(3.0-4.4)	<LOD	<LOD (<LOD-1.7)	2.9(2.5-3.4)	8.1(6.9-11.1)	21.5(15.4-46.0)	56.6(26.0-74.8)
<b>Race/Ethnicity</b>							
MA	4.6(4.0-5.2)	<LOD (<LOD-1.6)	2.4(2.2-2.6)	4.2(3.8-5.2)	8.1(6.5-9.0)	14.5(11.4-20.3)	26.2(20.3-36.2)
NHB	4.7(4.0-5.6)	<LOD	2.0(1.6-2.2)	4.2(3.3-5.2)	9.4(7.6-10.9)	23.7(16.6-34.3)	39.2(26.0-79.2)
NHW	3.8(3.2-4.5)	<LOD	1.5(<LOD-1.8)	3.3(2.8-4.1)	7.6(6.0-9.5)	18.5(14.5-23.3)	38.8(22.6-59.2)
<b>Sex</b>							
Females	3.7(3.2-4.4)	<LOD	1.6(<LOD-1.8)	3.2(2.8-4.1)	7.0(6.0-8.0)	18.4(14.4-23.1)	32.8(23.3-46.0)
Males	4.2(3.6-4.9)	<LOD	1.6(1.5-1.9)	3.8(3.1-4.4)	8.4(7.5-9.9)	17.9(14.9-25.1)	44.1(21.9-61.5)
<b>2,2',4,4',5,5'-hexabromodiphenyl ether (BDE-153)</b>							
All Participants	5.7(5.1-6.3)	<LOD	2.4(<LOD-2.6)	4.8(4.1-5.3)	11.3(9.8-12.7)	32.6(27.9-40.3)	65.7(54.9-88.4)
<b>Age Groups</b>							
12-19 Years	8.1(6.7-9.7)	2.2(<LOD-2.7)	3.6(3.0-5.2)	7.4(6.0-9.5)	15.3(11.7-19.4)	30.8(22.9-44.2)	52.9(35.9-68.5)
20-39 Years	6.6(5.6-7.9)	<LOD	2.8(2.3-3.3)	5.4(4.7-6.3)	13.7(10.9-18.0)	34.6(22.5-59.6)	63.5(50.4-88.4)
40-59 Years	4.6(3.9-5.4)	<LOD	<LOD(<LOD-2.2)	3.6(3.1-4.4)	7.3(5.8-10.0)	28.5(16.1-42.7)	62.8(31.6-115.0)
> 60 Years	5.1(4.3-6.1)	<LOD	<LOD(<LOD-2.3)	3.9(3.3-5.1)	10.6(8.4-13.6)	45.3(20.9-58.9)	91.5(58.9-134.0)
<b>Race/Ethnicity</b>							
MA	5.1(4.3-6.1)	<LOD	2.7(<LOD-3.1)	4.7(4.2-5.4)	8.6(6.5-11.0)	17.2(13.0-25.2)	34.0(18.3-55.1)
NHB	6.1(5.4-6.8)	<LOD	2.4(2.2-2.8)	5.5(4.7-6.1)	12.9(9.8-16.5)	30.0(21.0-42.7)	53.0(36.8-63.3)
NHW	5.9(5.0-6.8)	<LOD	2.4(<LOD-2.7)	4.9(3.9-5.5)	11.9(9.8-14.7)	39.0(28.5-54.9)	75.9(58.0-93.2)
<b>Sex</b>							
Females	4.8(4.2-5.4)	<LOD	<LOD (<LOD-2.4)	4.0(3.4-5.0)	9.7(7.4-11.7)	25.9(20.2-31.6)	54.5(34.6-62.9)
Males	6.9(6.0-7.8)	<LOD	2.9(2.4-3.2)	5.5(4.7-6.5)	12.6(11.2-16.1)	47.2(31.0-62.9)	88.4(63.4-115.0)
<b>2,2',4,4',5,5'-hexabromobiphenyl (BB-153)</b>							
All Participants	2.3(1.8-2.9)	<LOD	0.9(<LOD-1.3)	2.1(1.9-2.4)	4.4(3.4-6.3)	12.8(6.6-25.5)	26.1(11.7-60.5)
<b>Age Groups</b>							
12-19 Years	0.7(0.6-0.8)	<LOD	<LOD	<LOD	1.0(0.8-1.4)	2.7(2.0-3.0)	3.7(2.9-4.7)
20-39 Years	1.6(1.3-2.1)	<LOD	<LOD(<LOD-0.9)	1.6(1.2-1.8)	3.0(2.3-3.9)	6.6(3.9-12.2)	12.2(7.0-36.7)
40-59 Years	3.4(2.6-4.4)	0.8(<LOD-1.5)	1.8(1.6-2.1)	2.9(2.4-3.2)	5.9(3.7-11.9)	15.9(7.9-38.9)	36.9(13.7-70.3)
> 60 Years	4.5(3.2-6.2)	1.4(1.2-1.6)	2.0(1.8-2.5)	3.4(2.8-4.5)	8.1(4.7-15.8)	25.0(8.8-69.8)	52.8(19.2-114.0)
<b>Race/Ethnicity</b>							
MA	1.1(0.9-1.3)	<LOD	<LOD	1.1(<LOD-1.3)	2.5(2.0-2.9)	6.0(3.5-8.6)	10.0(6.5-15.2)
NHB	2.4(1.6-3.4)	<LOD	0.8(<LOD-1.4)	2.1(1.6-2.8)	4.8(3.0-12.1)	13.9(7.0-38.2)	29.7(12.1-70.2)
NHW	2.7(2.1-3.4)	<LOD	1.2(0.9-1.6)	2.4(2.2-2.8)	4.9(3.4-7.3)	13.5(6.6-35.4)	34.1(11.6-70.3)
<b>Sex</b>							
Females	1.9(1.5-2.5)	<LOD	<LOD(<LOD-1.1)	2.0(1.6-2.2)	3.6(2.8-4.9)	9.7(4.6-27.5)	23.9(7.4-56.6)
Males	2.8(2.2-3.5)	<LOD	1.1(0.8-1.6)	2.6(2.2-3.1)	5.3(3.8-8.4)	15.8(9.3-27.2)	34.9(13.5-70.3)

Abbreviations: MA, Mexican Americans; NHB, Non-Hispanic Black; NHW, Non-Hispanic White.

**Table 4.** Geometric mean (GM) concentrations (ng/g lipid) of 2,2',4,4',5,5'-hexabromobiphenyl (BB-153), 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) and 2,2',4,4',5,5'-hexaBDE (BDE-153) in participants having a primary residence constructed before 1959, between 1960 and 1977 and after 1978, and in foreign born participants and participants born in the United States, adjusted for design sampling weights. All data adjusted for design sampling weights. p-Values for all pair wise comparisons are given.

Strata	Serum Level (ng/g lipid)						Group Comparison	Pair wise Comparisons		
	BB-153		BDE-47		BDE-153			BB-153	BDE-47	BDE-153
	GM (95% CI)	N	GM (95% CI)	N	GM (95% CI)	N		p-value	p-value	p-value
<b>Construction Year of Primary Residence</b>										
<1959	2.7(1.9-3.9)	574	19.8(16.6-23.6)	564	5.7(4.8-6.8)	575	>1978 vs. 1960-77	0.03	0.45	0.14
1960-77	2.6(2.0-3.4)	430	19.3(14.8-25.3)	428	5.0(3.9-6.4)	430	>1978 vs. <1959	0.10	0.78	0.49
>1978	2.2(1.8-2.7)	534	20.4(17.1-24.4)	536	6.2(5.1-7.5)	536	1960-77 vs. <1959	0.56	0.86	0.36
<b>Country of Origin</b>										
USA	2.6(2.0-3.3)	1658	20.7(17.4-24.6)	1647	6.0(5.4-6.7)	1664	USA vs. Other	<0.01	0.46	<0.01
Other	1.0(0.84-1.3)	373	19.4(17.1-22.0)	368	4.1(3.3-5.0)	374				

**Figure 1.** Geometric mean concentrations (ng/g lipid) and 95% confidence intervals adjusted for design sampling weights. Data stratified by age, race/ ethnicity (MA, Mexican-Americans; NHB, Non-Hispanic Black; and NHW, Non-Hispanic White) and sex. Congener abbreviations are given in Table 1. \* Estimate is below the highest limit of detection for individual samples.





## Literature Cited

1. NCEH *Third national report on human exposure to environmental chemicals*, National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC): Atlanta, Georgia, USA. 2005.
2. WHO *Environmental Health Criteria 192. Flame retardants: A general introduction*, International Program on Chemical Safety, WHO: Geneva, Switzerland. 1997.
3. Fries, G. F. The PBB episode in Michigan. an overall appraisal. *Crit Rev Toxicol* **1985**, *16*, 105-156.
4. WHO *Environmental Health Criteria 162. Brominated diphenyl ethers*, International Program on Chemical Safety, WHO: Geneva, Switzerland. 1994.
5. Sjödin, A.; Bergman, Å.; Jakobsson, E.; Kierkegaard, A.; Marsh, G.; Sellström, U. Identification and quantification of polybrominated diphenyl ethers (PBDEs) in the commercial product Bromkal 70-5 DE. *Organohalogen Comp* **1997**, *32*, 388-393.
6. Alae, M.; Arias, P.; Sjödin, A.; Bergman, Å. An overview of commercially used brominated flame retardants, their application, their use patterns in different countries/regions and possible modes of release. *Environ Int* **2003**, *29*, 683-689.
7. Thuresson, K.; Höglund, P.; Hagmar, L.; Sjödin, A.; Bergman, Å.; Jakobsson, K. Apparent half-lives of hepta- to decabrominated diphenyl ethers in human serum as determined in occupationally exposed workers. *Environ Health Perspect* **2006**, *114*, 176-181.

8. Jakobsson, K.; Thuresson, K.; Höglund, P.; Sjödin, A.; Hagmar, L.; Bergman, Å. A summary of exposures to polybrominated diphenyl ethers (PBDEs) in Swedish workers, and determination of half-lives of PBDEs. *Organohalogen Comp* **2003**, *61*, 17-20.
9. Birnbaum, L.; Staskal, D. F. Brominated flame retardants: Cause for concern? *Environ Health Perspect* **2004**, *112*, 9-17.
10. Stapleton, H. M. In *What's in your home? Determination of PBDEs in carpet samples and mattress pads*; The Seventh Annual Workshop on Brominated Flame Retardants in the Environment; National Institute of Standards and Technology: Gaithersburg, Maryland, 2005; p 67.
11. Sjödin, A.; Päpke, O.; Focant, J.-F.; Jones, R. S.; Pless-Mulloli, T.; Leontjew Toms, L.-M.; Herrmann, T.; Mueller, J.; Needham, L. L.; Patterson Jr, D. G. Concentration of polybrominated diphenyl ethers (PBDEs) in household dust from various countries - Is dust a major source of human exposure? *Organohalogen Comp* **2006**, *68*, 2181-2185.
12. Schechter, A.; Pavuk, M.; Päpke, O.; Ryan, J. J.; Birnbaum, L.; Rosen, R. Polybrominated diphenyl ethers (PBDEs) in U.S. mothers' Milk. *Environ Health Perspect* **2003**, *111*, 1723-1729.
13. Meironyté Guvenius, D.; Aronsson, A.; Ekman-Ordeberg, G.; Bergman, A.; Norén, K. Human prenatal and postnatal exposure to polybrominated diphenyl ethers, polychlorinated biphenyls, polychlorobiphenyls, and pentachlorophenol. *Environ Health Perspect* **2003**, *111*, 1235-1241.

14. Kalantzi, O. L.; Martin, F. L.; Thomas, G. O.; Alcock, R. E.; Tang, H. R.; Drury, S. C.; Carmichael, P. L.; Nicholson, J. K.; Jones, K. C. Different levels of polybrominated diphenyl ethers (PBDEs) and chlorinated compounds in breast milk from two U.K. regions. *Environ Health Perspect* **2004**, *112*, 1085-1091.
15. Vieth, B.; Herrmann, T.; Mielke, H.; Ostermann, B.; Pöpke, O.; Rüdiger, T. PBDE levels in human milk: the situation in Germany and potential influencing factors - a controlled study. *Organohalogen Comp* **2004**, *66*, 2643-2648.
16. Harden, F. A.; Toms, L.-M.; Moore, M.; Symons, R.; Ahokas, J.; Burniston, D. A.; Furst, P.; Mueller, J. Polybrominated diphenyl ethers in human milk from Australia. *Organohalogen Comp* **2005**, *67*, 662-666.
17. Moreland, K. B.; Landrigan, P. J.; Sjödin, A.; Gobeille, A. K.; Jones, R. S.; McGahee, E.; Needham, L. L.; Patterson Jr, D. G. Body burdens of polybrominated diphenyl ethers among urban anglers. *Environ Health Perspect* **2005**, *113*, 1689-1692.
18. Sjödin, A.; Pöpke, O.; McGahee, E. E. I.; Jones, R. S.; Focant, J.-F.; Pless-Mulloli, T.; Toms, L.-M.; Wang, R.; Zhang, Y.; Needham, L. L.; Herrmann, T.; Patterson Jr, D. G. Concentration of polybrominated diphenyl ethers (PBDEs) in house hold dust from various countries - inhalation a potential route of human exposure. *Organohalogen Comp* **2004**, *66*, 3817-3822.
19. Stapleton, H. M.; Dodder, N. G.; Offenberg, J. H.; Schantz, M. M.; Wise, S. Polybrominated diphenyl ethers in house dust and clothes dryer lint. *Environ Sci Technol* **2005**, *39*, 925-931.

20. Wu, N.; Herrmann, T.; Paepke, O.; Tickner, J.; Hale, R.; Harvey, E.; La Guardia, M.; McClean, M. D.; Webster, T. F. Human exposure to PBDEs: Associations of PBDE body burdens with food consumption and house dust concentrations. *Environ Sci Technol* **2007**, *41*, 1584-1589.
21. Norstrom, R. J.; Simon, M.; Moisey, J.; Wakeford, B.; Weseloh, D. V. C. Geographical distribution (2000) and temporal trends (1981 - 2000) of brominated diphenyl ethers in Great Lakes herring gull eggs. *Environ Sci Technol* **2002**, *36*, 4783-4789.
22. Eriksson, P.; Jakobsson, E.; Fredriksson, A. Brominated flame retardants: a novel class of developmental neurotoxicants in our environment? *Environ Health Perspect* **2001**, *109*, 903-908.
23. McDonald, T. A. A perspective on the potential health risk of PBDEs. *Chemosphere* **2002**, *46*, 745-755.
24. Sjödin, A.; Jones, R. S.; Lapeza, C. R.; Focant, J.-F.; McGahee, E. I.; Patterson Jr, D. G. Semi-Automated High-Throughput Extraction and Cleanup Method for the Measurement of Polybrominated Diphenyl Ethers, Polybrominated Biphenyls and Polychlorinated Biphenyls In Human Serum. *Anal Chem* **2004**, *76*, 1921-1927.
25. Bradley, R. A.; Srivastava, S. S. Correlation in Polynomial Regression. *The American Statistician* **1979**, *33*, 11-14.
26. Needham, L.; Patterson Jr, D. G.; Calafat, A. M.; Sjödin, A.; Turner, W.; Kuklennyik, Z. Distribution of halogenated environmental chemicals among people of different ages, races, and sexes in the United States. *Organohalogen Comp* **2006**, *68*, 484-487.

27. Sjödin, A.; Jones, R. S.; Focant, J.-F.; Lapeza, C. R.; Wang, R. Y.; McGahee, E. I.; Zhang Y; Turner, W. E.; Slazyk, B.; Needham, L. L.; Patterson Jr, D. G. Retrospective Time-Trend Study of Polybrominated Diphenyl Ether and Polybrominated and Polychlorinated Biphenyl Levels in Human Serum from the United States. *Environ Health Perspect* **2004**, *112*, 655-658.